Background and Aims: Vitamin D-dependent rickets type I (VDDR1) is an autosomal recessive disorder caused by mutations in the 25-hydroxyvitamin D 1-alpha-hydroxylase gene (CYP27B1). Mutations in CYP27B1 disrupt or lead to a total loss of the 1-α-hydroxylase activity and require treatment with physiological doses of calcitriol. Patients and Methods: A genetic analysis of the CYP27B1 gene was conducted in 22 Turkish patients with VDDR1 from 13 families. Presenting characteristics, biochemical features, treatment, and results from the genetic analysis are described. Results: A splice donor site mutation c.195 + 2T>G was found in 10 patients. The novel missense p.192K>E (c.574A>G) mutation was detected in 5 patients, and a novel missense p.197G>D (c.590G>A) mutation was found in 4 patients. A previously reported 7-bp duplication 1319-1325dupCCCACCC (Phe443Profs*24) in exon 8 was detected in 1 patient, and 1 patient was a compound heterozygote for the novel p.192K>E and the previously described 1319-1325dupCCCACCC mutations. A novel single base pair deletion, c.171_171delG, leading to a frameshift, was found in 1 patient. Conclusions: We identified 3 novel and 2 previously described mutations in the CYP27B1 gene. A marked phenotypical diversity was observed between families that carried identical mutations, suggesting phenotypical heterogeneity.

1.
Lips P: Vitamin D physiology. Prog Biophys Mol Biol 2006;92:4-8.
2.
Hughes MR, Malloy PJ, Kieback DG, Kesterson RA, Pike JW, Feldman D, O'Malley BW: Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 1988;242:1702-1705.
3.
Kim CJ: Vitamin D dependent rickets type I. Korean J Pediatr 2011;54:51-54.
4.
Fu GK, Lin D, Zhang MY, et al: Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 1997;11:1961-1970.
5.
Fraser D, Kooh SW, Kind HP, Holick MF, Tanaka Y, DeLuca HF: Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med 1973;289:817-822.
6.
Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN: Human Gene Mutation Database (HGMD): 2003 update. Hum Mut 2003;21:577-581.
7.
Untergrasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG: Primer3 - new capabilities and interfaces. Nucleic Acids Res 2012;40:e115.
8.
Koressaar T, Remm M: Enhancements and modifications of primer design program Primer3. Bioinformatics 2007;23:1289-1291.
9.
Gene Codes Corporation: Sequencher® version 5.3 sequence analysis software. http://www.genecodes.com.
10.
Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K: dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001;29:308-311.
11.
1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA: An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491:56-65.
12.
NHLBI GO Exome Sequencing Project (ESP): Exome Variant Server. University of Washington, Seattle, USA. http://evs.gs.washington.edu/EVS/ (accessed January 2015).
13.
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-249.
14.
Schwarz JM, Cooper DN, Schuelke M, Seelow D: MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 2014;11:361-362.
15.
Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073-1081.
16.
Choi Y, Sims GE, Murphy S, Miller JR, Chan AP: Predicting the functional effect of amino acid substitutions and indels. PLoS One 2012;7:e46688.
17.
Buchan DWA, Minneci F, Nugent TCO, Bryson K, Jones DT: Scalable web services for the PSIPRED Protein Analysis Workbench. Nucleic Acids Res 2013;41: W349-W357.
18.
Durmaz E, Zou M, Al-Rijjal RA, Bircan I, Akçurin S, Meyer B, Shi Y: Clinical and genetic analysis of patients with vitamin D-dependent rickets type 1A. Clin Endocrinol (Oxf) 2012;77:363-369.
19.
Wang JT, Lin CJ, Burridge SM, Fu GK, Labuda M, Portale AA, Miller WL: Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families. Am J Hum Genet 1998;63:1694-1702.
20.
Elidrissy AT, Munawarah M, Alharbi KM: Hypocalcemic rachitic cardiomyopathy in infants. J Saudi Heart Assoc 2013;25:25-33.
21.
Kim BG, Chang SK, Kim SM, Hwang JS, Jung JW: Dilated cardiomyopathy in a 2 month-old infant: a severe form of hypocalcemia with vitamin D deficient rickets. Korean Circ J 2010;40:201-203.
22.
Yilmaz O, Olgun H, Ciftel M, Kilic O, Kartal I, Iskenderoglu NY, Laloglu F, Ceviz N: Dilated cardiomyopathy secondary to rickets-related hypocalcaemia: eight case reports and a review of the literature. Cardiol Young 2015;25:261-266.
23.
Root AW, Diamond FB: Disorders of mineral homeostasis in children and adolescents; in Sperling MA (ed): Pediatric Endocrinology, ed 4. Philadelphia, Saunders Elsevier, 2014, pp 734-845.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.